Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kwizera, Richard ^a   Nguna, Joyce ^a   Kiragga, Agnes ^a   Nakavuma, Jesca ^a   Rajasingham, Radha ^a,b   Boulware, David R ^a   Meya, David B ^a,b,c  

^a MAKERERE UNIVERSITY   (Uganda)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

CRYPTOCOCCAL ANTIGEN; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL EQUIPMENT; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ETHNIC GROUP; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LATERAL FLOW ASSAY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; POINT OF CARE TESTING; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; UGANDA; UGANDAN; COMPLICATION; FILOBASIDIELLA; IMMUNOLOGY; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; SALIVA;

ADULT; ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCUS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; SALIVA; SENSITIVITY AND SPECIFICITY; UGANDA;

EID: 84905391246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103156     Document Type: Article

References (16)

1. Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, et al. (2013) Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr 63: e101-108.
2. French N, Gray K, Watera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031-1038. (Pubitemid 34499426)
3. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935. (Pubitemid 47245826)
4. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
5. Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR (2012) Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med 9: e1001316.
6. Butler EK, Boulware DR, Bohjanen PR, Meya DB (2012) Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One 7: e51291.
7. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, et al. (2010) Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 10: 67.
8. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
9. Rajasingham R, Meya DB, Boulware DR (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85-91.
10. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, et al. (2013) Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa. PLoS One 8: e69288.
11. Alemu AS, Kempker RR, Tenna A, Smitson C, Berhe N, et al. (2013) High prevalence of cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One 8: e58377.
12. Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, et al. (2014) Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 20: 45-53.
13. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019-1023.
14. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 53: 321-325.
15. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, et al. (2014) Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370: 2487-2498.
16. World Health Organization (2011) Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization. Available: www.who.int/hiv/pub/ cryptococcal-disease2011. Accessed 2012 May 31.